Source: Magellan Financial Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Andrew Formica will assume the role of Executive Chairman at Magellan Financial Group (ASX:MFG)
  • David George steps down as CEO and MD of Magellan Asset Management, and a search for a new CEO is underway
  • Magellan continues in its efforts to become a leading fund manager in Australia
  • MFG is down almost three per cent, trading at $6.34 at 11:03 am AEDT

Magellan Financial Group (ASX:MFG) has announced changes in its leadership with the appointment of Andrew Formica as Executive Chair, following the resignation of David George from his role as CEO and Managing Director of Magellan Asset Management.

Mr George has also stepped down from his position as a Director of the Board with immediate effect.

Magellan also announced that Mr George would remain available for a handover until December 31, 2023, during which he will be compensated for the balance of six months’ notice.

“The Board, in consultation with David, believes it’s time to refocus our leadership to accelerate the progress we’ve made. Our immediate focus is on retaining, attracting, and incentivising our talent to drive performance excellence,” Mr Formica said.

To achieve this goal, Magellan is addressing Employee Share Purchase Plan (ESPP) Loans and plans to provide additional retention payments to clear ESPP Loan balances for most staff by September 2025

Moreover, the company is in the process of developing a new employee accountability and alignment model for short-term and long-term incentives, with a specific emphasis on aligning these incentives with positive client and shareholder outcomes. This new model is expected to be implemented by June 30, 2024.

MFG shares were down almost three per cent, trading at $6.34 at 11:03 am AEDT.

MFG by the numbers
More From The Market Online
Rio de Janeiro

Equinox finds shallow and high-grade titanium ahead of MRE for Brazilian play

Equinox Resources Ltd has picked up a suite of strong results in titanium oxide and total…
Singapore skyline

Firebrick Pharma launching retail Nasodine sales in Singapore

Firebrick Pharma (ASX:FRE) has inked a deal with Guardian, a pharmacy chain in Singapore, to launch…
FDA HQ

Neurotech bounces back from FDA rejection with new NTI164 baseline study

Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching…
Vietnam flag

TruScreen Group launches five-year cervical screening program in Ho Chi Minh City

TruScreen Group (ASX:TRU) has opted to launch a five-year cervical cancer screening run in Vietnam's Ho…